Search Results - "Due, Hanne"

Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review by Madsen, Marie Lindhard, Due, Hanne, Ejskjær, Niels, Jensen, Paw, Madsen, Jakob, Dybkær, Karen

“…Purpose Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive…”
Get full text

Hsp90 inhibition sensitizes DLBCL cells to cisplatin by Schmidt, Linnéa, Issa, Issa Ismail, Haraldsdóttir, Hulda, Hald, Jonas Laugård, Schmitz, Alexander, Due, Hanne, Dybkær, Karen

“…Purpose Platinum-containing therapy is standard treatment for relapsed Diffuse Large B-Cell Lymphoma (DLBCL). However, the efficacy of treatment is limited by…”
Get full text

MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index by Due, Hanne, Brøndum, Rasmus Froberg, Young, Ken H, Bøgsted, Martin, Dybkær, Karen

“…Treatment resistance is a major clinical challenge of diffuse large B-cell lymphoma (DLBCL) where approximately 40% of the patients have refractory disease or…”
Get full text

miR-155 as a Biomarker in B-Cell Malignancies by Dybkær, Karen, Roug, Anne Stidsholt, Johnsen, Hans Erik, Bøgsted, Martin, Schmitz, Alexander, Bødker, Julie Støve, Svendsen, Pernille, Due, Hanne, El-Galaly, Tarec Christoffer

“…MicroRNAs have the potential to be useful biomarkers in the development of individualized treatment since they are easy to detect, are relatively stable during…”
Get full text

Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma by Thomsen, Emil Aagaard, Rovsing, Anne Bruun, Anderson, Mads Valdemar, Due, Hanne, Huang, Jinrong, Luo, Yonglun, Dybkær, Karen, Mikkelsen, Jacob Giehm

“…Diffuse large B‐cell lymphoma (DLBCL) is characterized by extensive genetic heterogeneity, and this results in unpredictable responses to the current…”
Get full text

Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis by Jespersen, Ditte Starberg, Schönherz, Anna A., Due, Hanne, Bøgsted, Martin, Sondergaard, Teis Esben, Dybkær, Karen

“…Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with diverse clinical presentation and outcome. Bio-clinical prognostic models including…”
Get full text

CDCA2 Is a Predictive Marker and Mediator of Bortezomib Response in Diffuse Large B-Cell Lymphoma by Due, Hanne, Issa, Issa Ismail, Thomsen, Martin, Jakobsen, Maja Zimmer, Haraldsdóttir, Hulda, Brøndum, Rasmus Froberg, Dybkaer, Karen

“…Objective: In recent years randomized phase III clinical trials have attempted to improve first-line R-CHOP treatment of diffuse large B-cell lymphoma (DLBCL)…”
Get full text

Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP by Dybkær, Karen, Due, Hanne, Brøndum, Rasmus Froberg, Young, Ken H., Bøgsted, Martin

“…Background: Patients with Diffuse large B-cell lymphoma (DLBCL) in approximately 40% of cases suffer from primary refractory disease and treatment induced…”
Get full text

CRISPR-Cas9 Knockout Screens Identify DNA Damage Response Pathways and BTK as Essential for Cisplatin Response in Diffuse Large B-Cell Lymphoma by Issa, Issa Ismail, Due, Hanne, Brøndum, Rasmus Froberg, Veeravakaran, Vidthdyan, Haraldsdóttir, Hulda, Sylvester, Cathrine, Brogaard, Asta, Dhanjal, Soniya, Schmierer, Bernhard, Dybkær, Karen

“…The recurrence of diffuse large B-cell lymphoma (DLBCL) has been observed in 40% of cases. The standard of care for refractory/relapsed DLBCL (RR-DLBCL) is…”
Get full text

Beneficial Effect of Microrna-155 in Vincristine Response and Clinical Outcome in Especially GCB Diffuse Large B-Cell Lymphoma by Due, Hanne, Schönherz, Anna Amanda, Ryø, Laura Barett, Roug, Anne Stidsholt, Johnsen, Hans Erik, Bøgsted, Martin, Mikkelsen, Jacob Giehm, Dybkær, Karen

“…▪ R-CHOP is standard treatment for previously untreated diffuse large B-cell lymphoma (DLBCL). Approximately 35-40% of patients relapse following R-CHOP due to…”
Get full text

High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients by Laursen, Maria Bach, Reinholdt, Linn, Schönherz, Anna Amanda, Due, Hanne, Jespersen, Ditte Starberg, Grubach, Lykke, Ettrup, Marianne Schmidt, Røge, Rasmus, Falgreen, Steffen, Sørensen, Suzette, Bødker, Julie Støve, Schmitz, Alexander, Johnsen, Hans E, Bøgsted, Martin, Dybkær, Karen

“…Survival of diffuse large B-cell lymphoma (DLBCL) patients has improved by inclusion of rituximab. Refractory/recurrent disease caused by treatment resistance…”
Get full text

A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma by Issa, Issa Ismail, Brøndum, Rasmus Froberg, Due, Hanne, Schmidt, Linnéa, Bøgsted, Martin, Dybkær, Karen

“…: Bendamustine is primarily used for treatment of indolent lymphomas but has shown efficacy in some patients with diffuse large B-cell lymphoma (DLBCL) and…”
Get full text

MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma by Due, Hanne, Schönherz, Anna Amanda, Ryø, Laura, Primo, Maria Nascimento, Jespersen, Ditte Starberg, Thomsen, Emil Aagaard, Roug, Anne Stidholt, Xiao, Min, Tan, Xiaohong, Pang, Yuyang, Young, Ken H., Bøgsted, Martin, Mikkelsen, Jacob Giehm, Dybkær, Karen

“…A major clinical challenge of diffuse large B-cell lymphoma (DLBCL) is that up to 40% of patients have refractory disease or relapse after initial response to…”
Get full text

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis by Bødker, Julie Støve, Brøndum, Rasmus Froberg, Schmitz, Alexander, Schönherz, Anna Amanda, Jespersen, Ditte Starberg, Sønderkær, Mads, Vesteghem, Charles, Due, Hanne, Nørgaard, Caroline Holm, Perez-Andres, Martin, Samur, Mehmet Kemal, Davies, Faith, Walker, Brian, Pawlyn, Charlotte, Kaiser, Martin, Johnson, David, Bertsch, Uta, Broyl, Annemiek, van Duin, Mark, Shah, Rajen, Johansen, Preben, Nørgaard, Martin Agge, Samworth, Richard J., Sonneveld, Pieter, Goldschmidt, Hartmut, Morgan, Gareth J., Orfao, Alberto, Munshi, Nikhil, Johnson, Hans Erik, El-Galaly, Tarec, Dybkær, Karen, Bøgsted, Martin

“…Despite the recent progress in treatment of multiple myeloma (MM), it is still an incurable malignant disease, and we are therefore in need of new risk…”
Get full text

Molecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission by Bødker, Julie Støve, Severinsen, Marianne Tang, El-Galaly, Tarec Christoffer, Brøndum, Rasmus Froberg, Laursen, Maria Bach, Falgreen, Steffen, Nyegaard, Mette, Schmitz, Alexander, Jakobsen, Lasse Hjort, Schönherz, Anna Amanda, Due, Hanne, Reinholdt, Linn, Bøgsted, Martin, Dybkær, Karen, Johnsen, Hans Erik

“…The concept of precision medicine in cancer includes individual molecular studies to predict clinical outcomes. In the present N = 1 case we retrospectively…”
Get full text

Molecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission by Bødker, Julie Støve, Severinsen, Marianne Tang, El-Galaly, Tarec Christoffer, Brøndum, Rasmus Froberg, Laursen, Maria Bach, Falgreen, Steffen, Nyegaard, Mette, Schmitz, Alexander, Jakobsen, Lasse Hjort, Schönherz, Anna Amanda, Due, Hanne, Reinholdt, Linn, Bøgsted, Martin, Dybkær, Karen, Johnsen, Hans Erik

“…BACKGROUNDThe concept of precision medicine in cancer includes individual molecular studies to predict clinical outcomes. In the present N = 1 case we…”
Get full text